Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
INmune Bio, Inc. (INMB) had Stock-Based Compensation of $7.37M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$0.15M |
|
$-30.01M |
|
-- |
|
$0.15M |
|
$29.90M |
|
$-29.74M |
|
$-0.27M |
|
$-30.01M |
|
$-30.01M |
|
$-30.01M |
|
$-30.01M |
|
$-30.01M |
|
$-30.01M |
|
$-29.74M |
|
$-29.52M |
|
17.98M |
|
17.98M |
|
$-1.67 |
|
$-1.67 |
|
| Balance Sheet Financials | |
$39.94M |
|
-- |
|
$17.06M |
|
$57.00M |
|
$18.46M |
|
-- |
|
$1.20M |
|
$19.66M |
|
$37.34M |
|
$20.83M |
|
$37.34M |
|
17.95M |
|
| Cash Flow Statement Financials | |
$-11.98M |
|
-- |
|
$-4.22M |
|
$52.15M |
|
$35.85M |
|
$-16.30M |
|
|
Stock-Based Compensation |
$7.37M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.16 |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
100.00% |
|
-19187.74% |
|
-19187.74% |
|
-19043.22% |
|
-19360.00% |
|
-19360.00% |
|
$-11.98M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.06 |
|
5750.52 |
|
-80.36% |
|
-144.09% |
|
-52.64% |
|
-80.36% |
|
$2.08 |
|
$-0.67 |
|
$-0.67 |
|